Novo
Nordisk to ax 1,000 jobs in cost-cutting drive
Send a link to a friend
[September 29, 2016]
By Annabella PultzNielsen
COPENHAGEN (Reuters) - The world's largest
insulin maker, Novo Nordisk, is cutting 1,000 jobs as a part of a plan
to reduce costs as it faces a challenging environment in 2017,
especially in the large U.S. market, the company said on Thursday.
|
The Danish company, which has a global workforce of 42,300, said
about 500 of the lay-offs would be in Denmark. The headcount
reduction and associated costs would not change the financial
outlook for 2016, it said.
"We have concluded that it is needed in order for us to have a
sustainable balance between income and costs," Chief Executive Lars
Rebien Sorensen said in a statement.
Novo gets about half its revenue from the United States where there
are some 30 million diabetics but prices have been squeezed by
pharmacy benefit managers (PBMs) who administer drug benefits for
employers and health plans.

At its half-year results in August Novo cut its full-year profit
forecast, primarily due to the challenging U.S. market, knocking 8
percent of its Copenhagen-listed shares on the day.
Novo said the job cuts would affect research and development (R&D)
units and headquarter staff functions, as well as positions in the
global commercial organization.
"That they cut hard in R&D poses a risk in the long term, as in
whether they can keep momentum going. They are messing with their
life-blood which means that there isn't much fat left to cut off,"
Alm. Brand analyst Michael Friis Jorgensen said.
Jorgensen said he estimated the cuts would save Novo about 700
million to 1 billion crowns ($105-150 million), equivalent to 2-3
percent of next year's earnings before interest and tax.
[to top of second column] |

The job reductions come at a time of significant change at Novo,
which announced four weeks ago that long-serving CEO Sorensen would
step down in January. He will be succeeded by Lars Fruergaard
Jorgensen, who is now executive vice president and head of corporate
development.
($1 = 6.6417 Danish crowns)
(Additional reporting by Nikolaj Skydsgaard; editing by Ben
Hirschler and David Clarke)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.

 |